

Special Issue

Pharmacoepidemiology and Pharmacovigilance in the UK

Message from the Guest Editor

The UK has a long tradition of pharmacoepidemiology and pharmacovigilance; with a publicly funded system that provides universal health care, and electronic systems capturing a wide range of data, it is in a favourable position to conduct population-wide research in these areas. Considering developments such as an increasing population age, economic challenges, and public health threats such as the recent COVID-19 pandemic, obtaining an overview of current research and ongoing surveillance activities in the UK is warranted. For this Special Issue, authors are invited to submit original research and comprehensive reviews on all aspects related to pharmacoepidemiology and pharmacovigilance in the UK. This may include (but is not restricted to) manuscripts focusing on methodological developments; clinically relevant findings; clinical and/or cost-effectiveness; and the relevance of research and its impact on clinical practice. I look forward to receiving your contributions.

Guest Editor

Dr. Tanja Mueller

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

Deadline for manuscript submissions

28 February 2025



Pharmacoepidemiology

an Open Access Journal
by MDPI



mdpi.com/si/208288

Pharmacoepidemiology
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





Pharmacoepidemiology

an Open Access Journal
by MDPI



[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Carlotta Franchi

Department of Health Policy, Head of Laboratory of
Pharmacoepidemiology and Human Nutrition, Istituto di Ricerche
Farmacologiche Mario Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 6.3 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.